CLDI · XBRL financial data

Calidi Biotherapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (CLDI's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Research and development	3,251	3,958*	2,743	2,167	2,153	1,815*	2,425	2,593	2,361	2,358*	2,587	2,558
Selling, general and administrative	3,970	5,862*	4,009	3,605	3,073	2,211*	2,637	3,071	2,687	2,108*	1,600	1,592
Total operating expenses	7,221	9,820*	6,752	5,772	5,226	4,026*	5,062	5,664	5,048	4,466*	4,187	4,150
Operating income (loss)	(7,221)	(9,820)*	(6,752)	(5,772)	(5,226)	(4,026)*	(5,062)	(5,664)	(5,048)	(4,466)*	(4,187)	(4,150)
Interest expense	300	300*	300	200	200	100*	100	40	27	0*	23	23
Other income (expense)	(8)	(22)*	(17)	10	8	8*	(10)	(22)	18	117*	73	31
Income tax expense (benefit)	11	(3)*	4	8	(1)	3*	3	4	10	(2)*	4	5
Net income (loss)	(2,024)	(8,229)*	(7,225)	(5,767)	(5,054)	(4,097)*	(5,062)	(5,715)	(5,149)	(4,056)*	(4,108)	(4,160)
Earnings per share, basic USD per share	(0.14)	—	(0.20)	(1.40)	(0.65)	—	(0.18)	(1.99)	(2.21)	—	(0.43)	(2.94)
Earnings per share, diluted USD per share	(0.14)	—	(0.20)	(1.40)	(0.65)	—	(0.18)	(1.99)	(2.21)	—	(0.43)	(2.94)
Weighted average shares, basic thousands of shares	14,310	—	35,552	5,328	7,824	—	27	3	5	—	10,308	1,416
Weighted average shares, diluted thousands of shares	14,310	—	35,552	5,328	7,824	—	27	3	5	—	10,308	1,416

Fiscal quarters (CLDI's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	10,365	2,167	1,200	800	1,900	9,600	10,779	5,379	10,594	5,819	6,850	4,290
Prepaid and other current assets	1,540	2,354	793	789	324	636	928	770	653	656	722	1,357
Total current assets	11,687	4,303	1,936	1,625	2,221	10,227	11,489	6,049	11,028	6,256	7,353	5,428
Property and equipment, net	—	1,270	1,165	1,061	982	869	795	929	849	781	758	775
Right-of-use asset	4,331	4,073	3,798	3,518	3,237	2,934	2,636	2,333	2,012	1,682	1,342	992
Total assets	18,587	10,019	7,405	6,431	6,657	14,182	15,064	9,351	14,029	8,857	9,591	7,204
Current portion of long-term debt	3,345	807	4,236	2,983	3,112	3,221	1,155	820	472	90	23	45
Total current liabilities	10,873	10,232	14,953	13,052	11,579	9,496	5,426	5,353	5,193	3,935	3,836	3,237
Lease liability, non-current	3,299	3,037	2,756	2,461	2,161	1,845	1,523	993	640	277	6	5
Total liabilities	19,681	18,254	21,978	18,183	16,455	12,214	7,765	7,275	6,831	5,098	4,656	4,071
Accumulated deficit	(91,343)	(99,572)	(106,797)	(112,564)	(117,618)	(121,715)	(126,701)	(132,416)	(137,565)	(141,621)	(145,729)	(149,889)
Total stockholders' equity	(1,094)	(8,235)	(14,573)	(11,752)	—	1,534	6,941	1,764	6,918	3,759	4,935	3,133
Total liabilities and equity	18,587	10,019	7,405	6,431	6,657	14,182	15,064	9,351	14,029	8,857	9,591	7,204
Common shares outstanding (cover page) thousands of shares	35,436	35,538	50,924	8,084	13,078	28,468	31,793	3,426	7,168	10,896	19,312	2,584

Fiscal quarters (CLDI's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(2,024)	(8,229)*	(7,225)	(5,767)	(5,054)	(4,097)*	(5,062)	(5,715)	(5,149)	(4,056)*	(4,108)	(4,160)
Stock-based compensation	1,109*	1,186*	888	751*	692*	626*	607	522*	529*	450*	231	157*
Net cash from operating activities	(22,371)*	(5,186)*	(3,831)	(5,494)*	(4,946)*	(5,423)*	(7,131)	(4,880)*	(4,238)*	(5,044)*	(4,116)	(4,353)*
Net cash from investing activities	277*	(35)*	(5)	0*	(6)*	(5)*	(7)	(57)*	(27)*	(79)*	(5)	(33)*
Net cash from financing activities	31,280*	(2,958)*	3,013	5,200*	6,046*	13,106*	8,108	(469)*	9,480*	340*	5,159	1,829*
Net change in cash	9,199*	(8,198)*	(806)	(307)*	1,061*	7,694*	970	(5,400)*	5,215*	(4,775)*	1,031	(2,560)*

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Calidi Biotherapeutics	4,290	not reported	(4,353)*	2.6M	1.0 quarters	Q2 FY26 10-QJun 30, 2026
Processa Pharmaceuticals	196	not reported	(1,996)*	2.8M	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Talphera	742	not reported	(3,924)*	51.9M	4.4 quarters	Q2 FY26 10-QJun 30, 2026
Orgenesis	78	301*	(2,098)*	9.8M	0.0 quarters	Q4 FY24 10-KDec 31, 2024
Biovie	8,977	not reported	(4,122)*	7.5M	2.2 quarters	Q4 FY26 10-KJun 30, 2026
VivoSim Labs	1,670	18	(3,213)	14.9M	0.5 quarters	Q1 FY27 10-QJun 30, 2026
Genprex	15,154	not reported	(5,139)*	819,709	2.9 quarters	Q2 FY26 10-QJun 30, 2026
GT Biopharma	4,960	not reported	(4,260)*	45.1M	1.2 quarters	Q2 FY26 10-QJun 30, 2026
Intensity Therapeutics	9,529	not reported	(2,340)*	3.3M	4.1 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.